Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

On Friday, BIIB stock gained nearly 3%, bringing its trailing-five-day return to more than 5%. In the past month, BIIB has ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the ...